Compare FLO & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLO | OCUL |
|---|---|---|
| Founded | 1919 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2000 | 2014 |
| Metric | FLO | OCUL |
|---|---|---|
| Price | $8.79 | $8.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $13.67 | ★ $22.90 |
| AVG Volume (30 Days) | 6.0M | ★ 7.8M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 11.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $5,256,479,000.00 | $1,990,000.00 |
| Revenue This Year | N/A | $9.35 |
| Revenue Next Year | $0.67 | $92.88 |
| P/E Ratio | $21.58 | ★ N/A |
| Revenue Growth | 3.00 | ★ 3.48 |
| 52 Week Low | $8.46 | $6.23 |
| 52 Week High | $20.23 | $16.44 |
| Indicator | FLO | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 31.77 | 42.27 |
| Support Level | N/A | $8.36 |
| Resistance Level | $11.24 | $12.49 |
| Average True Range (ATR) | 0.32 | 0.71 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 18.91 | 8.63 |
Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.